CLEVELAND, Ohio (WPVI) -- A new blood test called the Iso-PSA is more accurate at predicting a man's risk at developing serious prostate cancer.
In a study presented today, the Iso-PSA was better at determining whether the cancer was low- or high-risk.
Developers say it could cut the number of false positives and unnecessary biopsies in half.
"It adds specificity for cancer. So if you have a worrisome PSA, it could be BPH, or could be cancer, you don't know, it's almost a coin flip. IsoPSA gives you a better sense of whether or not a biopsy is justified," says lead researcher Dr. Eric Klein of the Cleveland Clinic.
Aside from skin cancer, prostate cancer is the most common cancer in men.
The Iso-PSA test kit is in the process of getting F-D-A approval.
For more information on the test, click here.
New IsoPSA test promises more accuracy in finding prostate cancer
Developers predict 50% cut in false positives